17 December 2014
Ten years after California voters passed Proposition 71 on the promise that stem cell technology would produce new therapies, the board of the the California Institute for Regenerative Medicine (CIRM) last week unanimously approved $50 million for "CIRM 2.0" to accelerate the progress of clinical-stage programs.
Beginning Jan. 1, 2015, CIRM 2.0 initially will distribute awards to projects ready to start a clinical trial or for researchers who are doing the work required by the FDA to begin a clinical study. Grantee projects must be ready to start within 45 days of being approved for funding.
The stem cell agency will accept applications on a monthly basis from academia, industry, and non-California organizations offering to bring promising technology into the state.
In addition to funding, a Clinical Advisory Panel (CAP) will be established for each program. The CAP will consist of at least one of CIRM's internal science officers, outside experts, and at least one patient representative.
Voters passed the California Stem Cell Research and Cures Act in November 2004. The $50 million for CIRM 2.0 is part of the $3 billion in state bonds authorized by the ballot initiative.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Four cancer centers opened in Russia in 2023
26 April 2024
Russia and the UAE can simplify the drug registration process
26 April 2024
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024